BIBLIOGRAPHY


32. Horng-Chyuan Lin, Cha-Chun Tang, Ming-Shung Wu, Kuo-Shiung Huang, Han-Pin
Kuo, Chih-Teng Yu. Simple washing compared to dithiothreitol (DTT) method as a better method to preserve neutrophil activity in induced sputum. Thorac Med 2003; 18: 132-140. (Correspondent: Chih-Teng Yu).


67. Feng PH, Lin SM, Yu CT, Yu KH, Huang CD, Tsai YH, Kuo HP.


74. Chung FT, Chen HC, Chou CL, Yu CT, Kuo CH, Kuo HP, Lin SM.


(2) RESEARCH PROGRAMS:

1. CMRP-350. (Chang Gung Memorial Hospital 長庚紀念醫院)
   計劃名稱: The role of sensory neuropeptides in cigarette smoke-induced airway hyperresponsiveness.
   (Co-Investigator 共同主持人余志騰 Chihs-Teng Yu)
   (from 1992, 8 to 1994, 4)

2. NMRP-297. NSC82-0115-B182-086. (行政院國家科學委員會)
   計劃名稱: Effect of endogenous NO on plasma exudation in the airways.
   (Co-Investigator 共同主持人余志騰 Chihs-Teng Yu)
   (from 1993, 2 to 1994, 1)

3. CMRP-441. (Chang Gung Memorial Hospital 長庚紀念醫院)
   (Co-Investigator 共同主持人余志騰 Chihs-Teng Yu)
   (from 1994, 3 to 1995, 8).

4. CMRP-402. (Chang Gung Memorial Hospital 長庚紀念醫院)
   計劃名稱: Subpopulations of alveolar macrophages in patients with active pulmonary tuberculosis and pneumoconiosis.
   (Chief Investigator 主持人余志騰 Chihs-Teng Yu)
   (from 1993, 7 to 1995, 1)

5. CMRP-586. (Chang Gung Memorial Hospital 長庚紀念醫院)
   計劃名稱: Dynamic change of eosinophil cationic protein and EG2 induced by cytokines IL-3, IL-5 and GM-CSF.
   (Chief Investigator 主持人余志騰 Chihs-Teng Yu)
   (from 1996, 1 to 1996, 12)

6. NSC86-2314-B-182A-013 (行政院國家科學委員會)
   計劃名稱: Cigarette smoke exposure induces intracellular oxidant production and adhesion molecule expression to modulate neutrophil adherence to airway epithelial cell
7. CMRP-788. (Chang Gung Memorial Hospital 長庚紀念醫院)
   計劃名稱: The dynamic change of eosinophil subpopulations with resolution 
   of inflammation and apoptosis under anti-inflammatory treatment 
   in asthmatics. 
   (Chief Investigator Chih-Teng Yu 主持人俞志騰) 
   (from 1996, 8 to 1997, 7)

8. XMRP-138 (Chang Gung Memorial Hospital 長庚紀念醫院) (Abbott) 
   計劃名稱: A Comparative Study of the Safety and Efficacy of Clarithromycin 
   Modified Release and Clarithromycin in the Treatment of Acute 
   Exacerbation of Chronic Bronchitis 
   (Chief Investigator Chih-Teng Yu 主持人俞志騰) 
   (from 1999, 6 to 2000, 5)

9. XMRP-016 (Chang Gung Memorial Hospital 長庚紀念醫院) (Abbott) 
   計劃名稱: Clarithromycin 500 mg緩釋錠劑與 250 mg傳統錠劑於血中濃度 
   穩定狀態之藥物動態學試驗 
   (Chief Investigator Chih-Teng Yu 主持人俞志騰) 
   (from 2000, 3 to 2000, 8)

10. XMRP152 (Chang Gung Memorial Hospital 長庚紀念醫院) (Roche) 
    計劃名稱: An randomized, double-blind, placebo, controlled, multicentre, 
    phase III study of Tarceva™ (erlotinib) plus chemotherapy (Cisplatin 
    and Gemcitabine) versus chemotherapy alone in patients with advanced 
    stage IIIB or IV non-small cell lung cancer (NSCLC) who have not 
    received prior chemotherapy 
    protocol number: BO 16411 (Roche) 
    隨機、雙盲、具安慰劑，多中心之第三期研究試驗，以探討 Tarceva™ 
    (erlotinib)合併化學治療(Cisplatin 及 Gemcitabine)對單獨使用化學 
    治療，在先前未接受過化學治療之晚期(第 IIIB 或 IV 期)非小細胞肺 
    癌病患之療效及安全性 
    (Co-Investigator 共同主持人俞志騰 Chih-Teng Yu) 
    (from 20020701 to 20031231)

11. XMRP41747 (Chang Gung Memorial Hospital 長庚紀念醫院) 
    計劃名稱: 開放式、多中心、隨機分配、第三階段臨床試驗，評估口服用 Topotecan 
    與靜脈注射 Docetaxel 作用於曾經接受過治療之晚期(Stage IIIB/IV)之 
    非小細胞肺癌病人 
    (Co-Investigator 共同主持人俞志騰 Chih-Teng Yu) 
    (from 20020601 to 20040731)

12. XRP4174D-3001 (Chang Gung Memorial Hospital 長庚紀念醫院) 
    計劃名稱: International open label, randomized, multicentre phase III study of 
    irinotecan hydrochloride (Campto®) and cisplatin versus etoposide 
    and cisplatin in chemotherapy naïve patients with extensive disease 
    small cell lung cancer
XMRP521 (Chang Gung Memorial Hospital 長庚紀念醫院) (Roche) (RO 50-3821 Clinical Study Protocol)

計劃名稱: An open label, randomized, multicentre phase II study to determine hemoglobin dose response, safety and pharmacokinetic profile of Ro 50-3821 given subcutaneously once weekly or once every 3 weeks to anemic patients with stage IIIB or IV non-small cell lung carcinoma receiving antineoplastic therapy

計劃名稱: An open label, randomized, multicentre phase II study to determine hemoglobin dose response, safety and pharmacokinetic profile of Ro 50-3821 given subcutaneously once weekly or once every 3 weeks to anemic patients with stage IIIB or IV non-small cell lung carcinoma receiving antineoplastic therapy.

XMRP152- continued (Chang Gung Memorial Hospital 長庚紀念醫院) (Roche)

計劃名稱: A randomized, double-blind, placebo, controlled, multicentre, phase II study of Tarceva™ (erlotinib) plus chemotherapy (Cisplatin and Gemcitabine) versus chemotherapy alone in patients with advanced stage IIIB or IV non-small cell lung cancer (NSCLC) who have not received prior chemotherapy (continued Access programme)

郭軍, 隨機、平行、具安慰劑, 多中心之第三期臨床研究。以探討 TarcevaTM (erlotinib) plus chemotherapy (Cisplatin and Gemcitabine) versus chemotherapy alone in patients with advanced stage IIIB or IV non-small cell lung cancer (NSCLC) who have not received prior chemotherapy (continued Access programme).
16. LY231514  H3E-MC-JMDB  (Eli Lilly)  
(C Chang Gung Memorial Hospital 長庚紀念醫院)(565)  
計畫名稱: A randomized phase 3 trial of ALIMTA® and Cisplatin versus 
GEMZAR® and Cisplatin in patients with locally advanced or 
metastatic non-small cell lung cancer  
(Co-Investigator 共同主持人 余志勝 Chih-Teng Yu)  
(from 20040901 - )  
17. (Chang Gung Memorial Hospital 長庚紀念醫院)(智勝生技製藥公司)  
計畫名稱: 估計以 PEP03 用於治療慢性阻塞性肺疾病患者其療效、安全性、 
耐受性及其最佳使用劑量之研究  
(Co-Investigator 共同主持人 余志勝 Chih-Teng Y)  
(from 200403 - )  
18. (XMRP373) (Chang Gung Memorial Hospital 長庚紀念醫院)  
(EMR 62202-046) (Merck 公司)  
計畫名稱: 比較 Cisplatin/Vinorelbine 加上 Cetuximab 與 Cisplatin/Vinorelbine 
作為第一線治療適用於具表皮細胞生長因子受體(EGFR)表現的肺 
癌期非小細胞肺癌(NSCLC)患者之開放、隨機、對照性、多試驗 
中心第三期臨床試驗 (C 93-08-04)(長庚 93-249) 
Cetuximab in combination with cisplatin-based chemotherapy 
versus cisplatin-based chemotherapy alone as first-line treatment 
for patients with EGFR-expressing advanced non-small cell lung 
cancer (NSCLC)  
(Chief Investigator Chih-Teng Yu 主持人余志勝)  
(from 20041020-20081231)  
19. (XMRP410) (Chang Gung Memorial Hospital 長庚紀念醫院)  
(BO 17704) (Roche 公司)  
AVASTIN (bevacizumab) (RO 4876646) Clinical study protocol  
計畫名稱: A randomized, double-blind multicenter 2-stage phase III study of 
bevacizumab in combination with cisplatin and gemcitabine versus 
placebo, cisplatin and gemcitabine in patients with advanced or 
recurrent non-squamous non-small cell lung cancer, who have not 
receive prior chemotherapy.  
(Co-Investigator et al. 共同主持人 余志勝 Chih-Teng Yu)  
(from 20040621 - )  
20. (XMRP434) (Chang Gung Memorial Hospital 長庚紀念醫院)  
(Tarceva EAP:MO 181099) (Roche) (JIRB:93-12-04)  
計畫名稱: Tarceva TM (Erlotinib) 用於第三 B 期/第四期非小細胞肺癌 
(NSCLC)末期病人的另一試用(藥)計劃 
(Co-Investigator 共同主持人余志勝 Chih-Teng Yu)  
(from 20050307- )  
21. (NMRP: 計劃編號 NSC 94-2314-B-182-055-行政院國家科學委員會)  
計畫名稱: 肺癌病人的失眠問題：盛行率，特性，及對存活時間之衝擊
(Co-Investigator 共同主持人 余志騰 Chih-Teng Yu)
(計劃執行期限：From 2005-08-01 to 2006-07-31)
22. (NMPR: 計劃編號 NSC 94-2314-B-182A-107 行政院國家科學委員會)
計劃名稱：評估可開刀之 T1 及 T2 期肺癌其動態顯影電腦斷層與組織免疫組織化學檢查的血管發生因子(CD31, VEGF)/(1/2)
(Co-Investigator 共同主持人 余志騰 Chih-Teng Yu)
(計劃執行期限：From 2005-08-01 to 2006-07-31)

23. (NMPR: 計劃編號 NSC 95-2314-B-182-041-行政院國家科學委員會)
計劃名稱：肺癌病人化療期間疲憊及其症狀群集現象與能量保存活動處置介入措施之成效-縱貫性研究
(Co-Investigator 共同主持人 余志騰 Chih-Teng Yu)
(計劃執行期限：From 2006-08-01 to 2007-07-31)

24. (NMPR: 計劃編號 NSC 95-2314-B-182A-016 行政院國家科學委員會)
計劃名稱：評估可開刀之 T1 及 T2 期肺癌其動態顯影電腦斷層與組織免疫組織化學檢查的血管發生因子(CD31, VEGF)/(1/2)
(Co-Investigator 共同主持人 余志騰 Chih-Teng Yu)
(計劃執行期限：From 2006-08-01 to 2007-07-31)

25. (NMPR: 計劃編號 96-2314-B-182-030 行政院國家科學委員會)
計劃名稱：肺癌病患化療期間疲憊及其症狀群集現象與能量保存活動處置介入措施之成效-縱貫性研究
(Co-Investigator 共同主持人 余志騰 Chih-Teng Yu)
(計劃執行期限：From 2007/8/1 to 2008/7/31)

26. (NMPR: 計劃編號 97-2314-B-182-025 行政院國家科學委員會)
計劃名稱：能量保存活動處置對降低癌症疲憊之臨床試驗
(Co-Investigator 共同主持人 余志騰 Chih-Teng Yu)
(計劃執行期限：From 2008/8/1 to 2009/7/31)

27. (NMPR: 計劃編號 97-2314-B-182-041-MY3 行政院國家科學委員會)
計劃名稱：均質化電腦斷層與螺旋電腦斷層做為葡萄糖正子掃描之衰減校正圖像對肺部非小細胞型肺癌標準攝取值的影響
(Co-Investigator 共同主持人 余志騰 Chih-Teng Yu)
(計劃執行期限：From 2008/8/1 to 2011/7/31)

28. (NMPR: 計劃編號 98-2314-B-182-059-MY2 行政院國家科學委員會)
計劃名稱：穴位按壓對肺癌化療病人疲憊控制之成效：雙盲的實驗性研究
(Co-Investigator 共同主持人 余志騰 Chih-Teng Yu)
(計劃執行期限：From 2009/8/1 to 2011/7/31)